The prognostic advantage of calreticulin mutations in myelofibrosis might be confined to type 1 or type 1-like CALR variants

Ayalew Tefferi, Terra L. Lasho, Alexander Tischer, Emnet A. Wassie, Christy M. Finke, Alem A. Belachew, Rhett P. Ketterling, Curtis A. Hanson, Animesh D. Pardanani

Research output: Contribution to journalLetter

93 Scopus citations
Original languageEnglish (US)
Pages (from-to)2465-2466
Number of pages2
JournalBlood
Volume124
Issue number15
DOIs
StatePublished - Oct 9 2014

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Cite this

Tefferi, A., Lasho, T. L., Tischer, A., Wassie, E. A., Finke, C. M., Belachew, A. A., Ketterling, R. P., Hanson, C. A., & Pardanani, A. D. (2014). The prognostic advantage of calreticulin mutations in myelofibrosis might be confined to type 1 or type 1-like CALR variants. Blood, 124(15), 2465-2466. https://doi.org/10.1182/blood-2014-07-588426